Weight Change and Diabetes Medications: Is There an Association with Adherence and Discontinuation?

Author(s)

Boye K1, Shinde S2, Kennedy-Martin T3, Robinson S4, Thieu VT2
1Eli Lilly and Company, Greenwood, IN, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3KMHO Limited, Brighton, UK, 4KMHO Limited, Henfield, UK

OBJECTIVES: To conduct a systematic literature review exploring if weight change during treatment of type 2 diabetes (T2D) is associated with medication adherence and/or discontinuation.

METHODS: A literature search of MEDLINE, EMBASE, and recent congress abstracts was conducted to identify studies (January 2005 to September 2020) reporting objective data on weight change and adherence and/or discontinuation in people with T2D (PwD) treated with diabetes medications.

RESULTS: Nine studies were identified from 9188 records. Studies evaluated the association between weight change and adherence (n=6), discontinuation (n=2), and adherence and discontinuation (n=1). Four reported absolute weight change (kg) by adherence: three found the direction of change followed known weight profiles (loss or gain) of the evaluated drug; one demonstrated greater weight loss in adherent versus non-adherent PwD even when data from drugs with different weight profiles were pooled. Two studies reported the proportion of PwD achieving categorical weight loss (≥3%) by adherence: one showed that more adherent versus non-adherent PwD lost ≥3% weight within 3–6 months of glucagon-like peptide-1 agonist initiation; the second demonstrated that ≥3% weight loss occurred more commonly in adherent PwD regardless of weight profile of the evaluated drug. One study reported adherence according to categorical weight change: adherence improved with increasing weight loss regardless of the drug received (loss/gain profile). All three discontinuation studies reported that PwD who lost weight versus gained weight were less likely to discontinue therapy.

CONCLUSIONS: Our findings suggest weight gain is associated with discontinuation, but the relationship between on-treatment adherence and weight change is more complex. Further evidence from longitudinal studies is needed to evaluate causality between weight change on T2D medication and adherence/discontinuation. Supporting better diabetes medication adherence and persistence is key in improving outcomes; therefore, further exploration of weight as an important influencer in this regard is warranted.

Conference/Value in Health Info

2021-11, ISPOR Europe 2021, Copenhagen, Denmark

Value in Health, Volume 24, Issue 12, S2 (December 2021)

Code

POSA361

Topic

Patient-Centered Research

Topic Subcategory

Adherence, Persistence, & Compliance

Disease

Diabetes/Endocrine/Metabolic Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×